GW 275919
Latest Information Update: 02 Aug 2023
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammation; Pain
Most Recent Events
- 05 Sep 2000 Discontinued-II for Inflammation in United Kingdom (Unknown route)
- 05 Sep 2000 Discontinued-II for Pain in United Kingdom (Unknown route)
- 07 Feb 2000 Phase-II clinical trials for Inflammation in United Kingdom (Unknown route)